Form 13-F position report

ELEVATION ONCOLOGY INC

Reported by VANGUARD GROUP INC

Company profile Manager portfolio Source filing
ELEV CUSIP 28623U101 Manager CIK 0000102909
Latest reported change

Reported 2,256,690 shares, down 328,530 (12.7%) from the prior quarter.

Reported value 23.7%; share count -12.7% vs. the prior quarter.

Reduced
% of reported 13F value < 0.01% This manager · Q2 2025
Shares 2,256,690 Quarter-end amount reported
Reported value $828,205 Fair value at quarter end
Consecutive quarters held 17 Through Q2 2025

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Manager history

Quarterly position history

How this manager's reported quarter-end position changed over time.

18 quarters
Quarter Activity Shares Change % of reported 13F Reported value Filed
Q3 2025 Reduced 0 -2,256,690 (-100.0%) 0 $0 2025-11-07
Q2 2025 Reduced 2,256,690 -328,530 (-12.7%) < 0.01% $828,205 2025-08-11
Q1 2025 Reduced 2,585,220 -24,825 (-1.0%) < 0.01% $669,572 2025-05-09
Q4 2024 Reduced 2,610,045 -461,535 (-15.0%) < 0.01% $1,469,456 2025-02-11
Q3 2024 Added 3,071,580 +1,154,537 (60.2%) < 0.01% $1,842,947 2024-11-13
Q2 2024 Added 1,917,043 +384,998 (25.1%) < 0.01% $5,176,016 2024-08-13
Q1 2024 Added 1,532,045 +360,799 (30.8%) < 0.01% $7,859,391 2024-05-10
Q4 2023 Added 1,171,246 +101,441 (9.5%) < 0.01% $628,959 2024-02-14
Q3 2023 Reduced 1,069,805 -5,352 (-0.5%) < 0.01% $708,853 2023-11-14
Q2 2023 Added 1,075,157 +619,376 (135.9%) < 0.01% $1,634,239 2023-08-14
Q1 2023 Added 455,781 +122,473 (36.7%) < 0.01% $865,984 2023-05-15
Q4 2022 Added 333,308 +284 (0.1%) < 0.01% $316,643 2023-02-10
Q3 2022 Reduced 333,024 -66,766 (-16.7%) < 0.01% $376,000 2022-11-14
Q2 2022 Added 399,790 +23,637 (6.3%) < 0.01% $560,000 2022-08-12
Q1 2022 Reduced 376,153 -4,660 (-1.2%) < 0.01% $948,000 2022-05-13
Q4 2021 Reduced 380,813 -274,596 (-41.9%) < 0.01% $2,292,000 2022-02-14
Q3 2021 Added 655,409 +595,409 (992.3%) < 0.01% $5,106,000 2021-11-12
Q2 2021 New 60,000 +60,000 (0.0%) < 0.01% $814,000 2021-08-13
Institutional context

Who else reported the position

98 managers reported ELEVATION ONCOLOGY INC for Q2 2025.

Manager Activity Shares Change % of reported 13F Reported value Tenure
Frazier Life Sciences Management L P Unchanged 5,993,579 0 0.09% $2,200,243 5 qtrs
BML Capital Management LLC Reduced 5,890,434 -500 1.64% $2,162,378 2 qtrs
Aisling Capital Management LP Unchanged 2,834,910 0 0.29% $1,040,695 17 qtrs
VANGUARD GROUP INC This report Reduced 2,256,690 -328,530 < 0.01% $828,205 17 qtrs
Opaleye Management Inc New 1,442,061 +1,442,061 0.11% $529,381 1 qtr
DELTEC ASSET MANAGEMENT LLC New 1,436,363 +1,436,363 0.09% $527,289 1 qtr
MILLENNIUM MANAGEMENT LLC New 1,424,446 +1,424,446 < 0.01% $522,914 9 qtrs
SUSQUEHANNA INTERNATIONAL GROUP LLP Added 1,010,308 +941,871 < 0.01% $370,884 3 qtrs
Rangeley Capital LLC New 905,289 +905,289 0.4% $332,332 1 qtr
ExodusPoint Capital Management LP New 597,017 +597,017 < 0.01% $219,000 1 qtr
A free account expands this comparison to 25 managers. Create free account
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2025
Filed
August 11, 2025
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
0
None
2,256,690

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.